全文获取类型
收费全文 | 22146篇 |
免费 | 1441篇 |
国内免费 | 479篇 |
专业分类
耳鼻咽喉 | 148篇 |
儿科学 | 1122篇 |
妇产科学 | 340篇 |
基础医学 | 1922篇 |
口腔科学 | 47篇 |
临床医学 | 2809篇 |
内科学 | 2598篇 |
皮肤病学 | 111篇 |
神经病学 | 1286篇 |
特种医学 | 799篇 |
外国民族医学 | 2篇 |
外科学 | 4034篇 |
综合类 | 3092篇 |
现状与发展 | 2篇 |
预防医学 | 2001篇 |
眼科学 | 38篇 |
药学 | 2243篇 |
14篇 | |
中国医学 | 586篇 |
肿瘤学 | 872篇 |
出版年
2024年 | 50篇 |
2023年 | 302篇 |
2022年 | 461篇 |
2021年 | 822篇 |
2020年 | 781篇 |
2019年 | 729篇 |
2018年 | 760篇 |
2017年 | 713篇 |
2016年 | 745篇 |
2015年 | 768篇 |
2014年 | 1512篇 |
2013年 | 1532篇 |
2012年 | 1332篇 |
2011年 | 1388篇 |
2010年 | 1142篇 |
2009年 | 1096篇 |
2008年 | 1100篇 |
2007年 | 1096篇 |
2006年 | 989篇 |
2005年 | 851篇 |
2004年 | 733篇 |
2003年 | 600篇 |
2002年 | 528篇 |
2001年 | 468篇 |
2000年 | 370篇 |
1999年 | 361篇 |
1998年 | 314篇 |
1997年 | 265篇 |
1996年 | 216篇 |
1995年 | 193篇 |
1994年 | 166篇 |
1993年 | 158篇 |
1992年 | 171篇 |
1991年 | 126篇 |
1990年 | 124篇 |
1989年 | 109篇 |
1988年 | 102篇 |
1987年 | 86篇 |
1986年 | 106篇 |
1985年 | 124篇 |
1984年 | 94篇 |
1983年 | 74篇 |
1982年 | 102篇 |
1981年 | 75篇 |
1980年 | 52篇 |
1979年 | 35篇 |
1978年 | 36篇 |
1977年 | 27篇 |
1976年 | 22篇 |
1973年 | 11篇 |
排序方式: 共有10000条查询结果,搜索用时 156 毫秒
21.
22.
Biliary tract cancer, including cholangiocarcinoma (CCA) and gallbladder cancer (GBC) are rare tumours with a rising incidence. Prognosis is poor, since most patients are diagnosed with advanced disease. Only ~20% of patients are diagnosed with early-stage disease, suitable for curative surgery. Despite surgery performed with potentially-curative intent, relapse rates are high, with around 60–70% of patients expected to have disease recurrence. Most relapses occur in the form of distant metastases, with a predominance of liver spread. In view of high tumour recurrence, adjuvant strategies have been explored for many years, in the form of radiotherapy, chemo-radiotherapy and chemotherapy. Historically, few randomised trials were available, which included a variety of additional tumours (e.g. pancreatic and ampullary tumours); most evidence relied on phase II and retrospective studies, with no high-quality evidence available to define the real benefit derived from adjuvant strategies.Since 2017, three randomised phase III clinical trials have been reported; all recruited patients with resected biliary tract cancer (CCA and GBC) who were randomised to observation alone, or chemotherapy in the form of gemcitabine (BCAT study; included patients diagnosed with extrahepatic CCA only), gemcitabine and oxaliplatin (PRODIGE-12/ACCORD-18; included patients diagnosed with CCA and GBC) or capecitabine (BILCAP; included patients diagnosed with CCA and GBC). While gemcitabine-based chemotherapy failed to show an impact on patient outcome (relapse-free survival (RFS) or overall survival (OS)), the BILCAP study showed a benefit from adjuvant capecitabine in terms of OS (pre-planned sensitivity analysis in the intention-to-treat population and in the per-protocol analysis), with confirmed benefit in terms of RFS. Based on the BILCAP trial, international guidelines recommend adjuvant capecitabine for a period of six months following potentially curative resection of CCA as the current standard of care for resected CCA and GBC. However, BILCAP failed to show OS benefit in the intention-to-treat (non-sensitivity analysis) population (primary end-point), and this finding, as well as some inconsistencies between studies has been criticised and has led to confusion in the biliary tract cancer medical community.This review summarises the adjuvant field in biliary tract cancer, with evidence before and after 2017, and comparison between the latest randomised phase III studies. Potential explanations are presented for differential findings, and future steps are explored. 相似文献
23.
目前化疗仍为晚期胃癌的标准治疗手段,而多数患者诊断时已接近晚期。近年新兴的免疫治疗手段程序性死亡蛋白-1(PD-1,programmed death l)抗体,通过阻断肿瘤细胞逃避自身免疫机制,重新激活自身免疫对肿瘤的杀伤作用,从而达到肿瘤的治疗作用。针对晚期胃癌的PD-1抗体治疗的临床研究已在国内外开展,大部分均有较好效果。本文对近年免疫治疗中的PD-1抗体在晚期胃癌的重要临床研究进展进行介绍。 相似文献
24.
25.
Sumanta K. Pal MD Dean Bajorin MD Nazli Dizman MD Jean Hoffman-Censits MD David I. Quinn MD Daniel P. Petrylak MD Matthew D. Galsky MD Ulka Vaishampayan MD Ugo De Giorgi MD Sumati Gupta MD Howard A. Burris MD Harris S. Soifer PhD Gary Li PhD Hao Wang PhD Carl L. Dambkowski MD Susan Moran MD Siamak Daneshmand MD Jonathan E. Rosenberg MD 《Cancer》2020,126(11):2597-2606
26.
27.
施他宁联合奥美拉唑治疗肝硬化并上消化道大出血的疗效观察 总被引:1,自引:0,他引:1
目的探讨施他宁(生长抑素)联合奥美拉唑治疗肝硬化合并上消化道大出血的疗效。方法将确诊的83例患者随机分为三组。治疗组采用施他宁联合奥美拉唑的治疗方案,对照1组采用奥曲肽联合奥美拉唑的方案,对照2组采用垂体后叶素联合奥美拉唑的方案,观察时间为72 h。结果治疗组、对照1组、对照2组的止血有效率分别为93.3%、68.0%、57.1%,治疗组的止血有效率明显高于两个对照组(P<0.05);治疗组、对照1组、对照2组的有效止血时间分别为(29.71±6.35)h,(38.24±7.04)h,(40.88±9.98)h,治疗组的有效止血时间明显短于两个对照组(P<0.01)。结论施他宁联合奥美拉唑治疗肝硬化合并上消化道大出血疗效满意。 相似文献
28.
原位肝移植术后缺血型胆道病变20例 总被引:1,自引:1,他引:0
目的探讨原位肝移植术后缺血型胆道病变(ITBL)的病因及预防、诊断和治疗的措施。方法回顾性分析1999年2月至2005年4月间291例次原位肝移植后发生ITBL患者的临床资料。结果291例次原位肝移植术后共发生ITBL 20例(6.9%)。术后发生ITBL的高危因素为:原发病为重型乙型肝炎、供受者ABO血型不符、供肝冷保存时间超过12h和术后肝动脉病变。其发生率分别为12.5%(9/71)、20.0%(2/10)、11.1%(9/81)和60%(3/5)。采用药物、经内镜逆行胰胆管造影(ERCP)介入、胆道外科手术及再次肝移植等方法治疗,有效率为80.0%(16/20)、治愈率为50.0%(10/20),与ITBL相关的病死率为10.0%(2/20),与ITBL相关的移植物功能丧失发生率为20.0%(4/20)。结论针对ITBL的高危因素进行相应处理是预防ITBL的有效措施。胆道造影和核磁共振胆胰管成像对诊断ITBL有很高的敏感性和特异性。根据不同的病因和病变程度采用适当的方法治疗ITBL,可获得良好的疗效。 相似文献
29.
Urodynamic studies in the evaluation of young men presenting with lower urinary tract symptoms 总被引:1,自引:0,他引:1
AIM: To evaluate the usefulness of urodynamic study in young men with lower urinary tract symptoms (LUTS). METHODS: We reviewed the charts of 50 men with LUTS aged 50 years and below. Those with neurological diseases, urethral trauma or strictures were excluded. All underwent multichannel urodynamic studies (UDS). The pre- and post-UDS diagnoses and treatment modalities were compared. RESULTS: Mean age was 38.1 years (17-49). The main pre-UDS diagnoses included prostatitis in seven (14%), overactive bladder in seventeen (34%) and benign prostatic hyperplasia in nine (18%). Pre-UDS management ranged from anticholingeric agents for thirteen (26%), alpha-adrenergic antagonists for nine (18%), antibiotics for six (12%). Abnormal UDS were noted in 36 (72%), including detrusor overactivity in 9 (18%), detrusor underactivity/acontractility in 5 (10%) and bladder outlet obstruction in 21 (42%). Fourteen (28%) had primary bladder neck dysfunction and five (10%) had benign prostatic hyperplasia. Post-UDS management included anticholingeric agents for ten (26%), alpha-adrenergic antagonists for seventeen (34%), catheterization for four (10%), behavioral therapy for three (6%), surgery for three (6%). None were prescribed antibiotics. Following UDS, the diagnosis had to be updated in 40 (80%) and concomitant change in management was required in 34 (68%). CONCLUSION: Young men presenting with LUTS have different underlying etiologies. Clinical diagnosis and treatment are often empiric and inaccurate. Urodynamic study is useful in the evaluation of this group of patients as it aids in arriving at an accurate diagnosis and guides treatment therapy. 相似文献
30.